Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).

Neuroendocrine activation is known to occur in patients with congestive heart failure, but there is uncertainty as to whether this occurs before or after the presence of overt symptoms. In the Studies of Left Ventricular Dysfunction (SOLVD), a multicenter study of patients with ejection fractions of 35% or less, we compared baseline plasma norepinephrine, plasma renin activity, plasma atrial natriuretic factor, and plasma arginine vasopressin in 56 control subjects, 151 patients with left ventricular dysfunction (no overt heart failure), and 81 patients with overt heart failure before randomization. Median values for plasma norepinephrine (p = 0.0001), plasma atrial natriuretic factor (p less than 0.0001), plasma arginine vasopressin (p = 0.006), and plasma renin activity (p = 0.03) were significantly higher in patients with left ventricular dysfunction than in normal control subjects. Neuroendocrine values were highest in patients with overt heart failure. Plasma renin activity was normal in patients with left ventricular dysfunction without heart failure who were not receiving diuretics and was significantly increased (p less than 0.05) in patients on diuretic therapy. We conclude that neuroendocrine activation occurs in patients with left ventricular dysfunction and no heart failure. Neuroendocrine activation is further increased as overt heart failure ensues and diuretics are added to therapy.

[1]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[2]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[3]  C. Benedict,et al.  Rapid, simplified radioimmunoassay of arginine-vasopressin and atrial natriuretic peptide in plasma. , 1988, Clinical chemistry.

[4]  M. Pfeffer,et al.  Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. , 1988, The American journal of medicine.

[5]  N. Sharpe,et al.  TREATMENT OF PATIENTS WITH SYMPTOMLESS LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 1988, The Lancet.

[6]  J. Laragh,et al.  Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. , 1987, The American journal of cardiology.

[7]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[8]  P. Armstrong,et al.  Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. , 1986, Circulation.

[9]  C. Benedict,et al.  Radioenzymatic microassay for simultaneous estimations of dopamine, norepinephrine, and epinephrine in plasma, urine, and tissues. , 1985, Clinical chemistry.

[10]  M. Pfeffer,et al.  Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.

[11]  J. Cohn,et al.  Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. , 1985, Annals of internal medicine.

[12]  G. L. Neifeld Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure , 1985 .

[13]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[14]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[15]  G. Riegger,et al.  Role of the renin-angiotensin system in the development of congestive heart failure in the dog as assessed by chronic converting-enzyme blockade. , 1984, The American journal of cardiology.